Finoriq research workspace
BECTON DICKINSON & CO (BDX) SEC Filings & Filing Highlights
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices. Review BDX SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
- Company
- BECTON DICKINSON & CO (BDX)
- Ticker
- BDX
- Market Cap
- $42.8B
- Latest Price
- $155.38
- Industry
- Medical Devices
BECTON DICKINSON & CO (BDX) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for BECTON DICKINSON & CO (BDX).
| Event | Form | Date |
|---|---|---|
| As previously disclosed, on May 6, 2026, Becton, Dickinson and Company voluntarily placed Chlor...As previously disclosed, on May 6, 2026, Becton, Dickinson and Company ("BD") voluntarily placed ChloraPrep™ and PurPrep™ on ship hold in t... | 8-K7.01 | 2026-05-29 |
| Subsidiary Notes OfferingOn May 20, 2026, Becton Dickinson Euro Finance S.à r.l., a private limited liability company (société à responsabilité limitée) incorporate... | 8-K1.01 | 2026-05-20 |
| Certain of the Underwriters or their affiliates may hold a portion of the 1.208% Euro Notes and...On May 11, 2026, Becton, Dickinson and Company (“BD”), together with its indirect, wholly-owned subsidiary, Becton Dickinson Euro Finance S... | 8-K8.01 | 2026-05-12 |
| BECTON DICKINSON & CO: Earnings or resultsBD Reports Second Quarter Fiscal 2026 Financial Results | 8-K2.02 | 2026-05-07 |
| AMENDMENT TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEARAMENDMENT TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR | 8-K5.03 | 2026-04-29 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.